SPONSORED CONTENT
Q1 2026 started rougher than predicted for 340B programs. Ceiling prices compressed. Penny pricing disappeared on drugs that used to be your biggest savings. And an entire drug category that looked like a growth engine 12 months ago went dark almost overnight. Three forces. All hitting at once. And they’re not slowing down.
Each one compresses margins on its own. Together, they’re rewriting the financial math safety-net providers have relied on for years. The drugs that used to generate your biggest 340B savings are repricing themselves—and the manufacturers aren’t doing it out of generosity. They’re doing the math. But here’s what most programs are missing: these forces hit hardest when your TPA, your pharmacy operations and your referral capture are managed by disconnected vendors with disconnected data. Fragmentation was expensive before the IRA. Now it’s unsustainable.
So where does growth come from when existing margins are compressing?
Not from the drugs getting squeezed. From the prescriptions you’re already entitled to but aren’t capturing. Specialty referrals represent 340B-eligible volume most programs are leaving on the table, in drug categories these three forces haven’t touched.
One covered entity captured $600,000 in referral savings in the same period their previous approach found just $5,000. That’s not a rounding error. That’s a program transformation.
Patterns no single organization can see on its own—which drugs are hit hardest, where the growth opportunities are hiding and why some programs are pulling ahead while others fall behind.
What does the data show across 800-plus covered entities?
On April 22 at 1 p.m. ET, NuvemRx CEO Scott Seidelmann, Chief Clinical Officer Melissa Opraseuth and SVP of Mission Control Charlie Hirner will break down exactly how these three forces interact, show where the untapped growth is and share what the data from 800-plus covered entities reveals about the programs that are getting stronger right now—and what they’re doing differently.
Speakers and Topics They Will Cover:
Scott Seidelmann, CEO, NuvemRx
Scott leads NuvemRx’s vision for a clinically integrated pharmacy that integrates TPA, pharmacy management and referral capture into a single system built exclusively for safety-net providers. He’ll talk about the three forces NuvemRx sees impacting 340 programs today.
Melissa Opraseuth, Chief Clinical Officer, NuvemRx
Melissa oversees NuvemRx’s referral capture and clinical integration capabilities. Previously COO of par8o, the referral capture platform recently acquired by NuvemRx , she’ll show proof from covered entities that found their biggest untapped revenue source in prescriptions they didn’t know they were missing.
Charlie Hirner, SVP of Mission Control, NuvemRx
Charlie runs NuvemRx’s Mission Control—a team of dedicated experts backed by data from 800-plus covered entities, 70 million patients, and $2.6 billion in net savings. He’ll share what the network reveals about IRA impact at scale, and why the programs pulling ahead share one thing in common.
Please note: This event is limited to 340B covered entities.
